World Mental Health Day & Q4 Conference Schedule
TheraCryf PLC announced its participation in several industry and investor conferences during Q4 2025, including BioSeed North on October 21 in Manchester, BioEurope from November 3-5 in Vienna, the ShareSoc Growth Company Seminar on November 13, Mello London on November 18-19, and London Life Sciences Week & Jefferies Global Healthcare Conference from November 17-21 in London. This announcement coincides with World Mental Health Day, highlighting the company's focus on developing treatments for mental disorders, particularly through its Ox-1 programme targeting binge eating and substance use disorders, impacting over 1 billion people globally. The company anticipates clinical trials for its orexin-1 blocker within a year.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
Alderley Park, 10 October 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, notes that today is World Mental Health Day and also shares its conference schedule for Q4 2025.
World Mental Health Day
10 October is World Mental Health Day, aiming to raise awareness of mental health issues around the world and to mobilize efforts in support of mental health. Globally, more than 1 billion people live with a mental health condition*, with anxiety and depression being the most common, according to the World Health Organization.
TheraCryf is honoured to be contributing to the potential treatment of mental disorders such as anxiety and addictive behaviour through its lead Ox-1 programme, a class-leading orexin-1 antagonist, targeting binge eating disorder and other substance use disorders.
TheraCryf's Chief Operating Officer, Dr Helen Kuhlman, discusses the potential of orexin-based treatments for addictive behaviours in her article 'The Promise of Orexin-1 Antagonists in Addiction Treatment', in the most recent edition of European Biopharmaceutical Review.
*World Mental Health Today Report, September 2025
Q4 Conference Schedule
The TheraCryf leadership team will also be attending the following industry and investor conferences and events during Q4.
BioSeed North, 21 October 2025, Manchester
BioEurope, 3-5 November 2025, Vienna
ShareSoc Growth Company Seminar, 13 November 2025, London
Mello London, 18-19 November 2025, London
London Life Sciences Week & Jefferies Global Healthcare Conference, 17-21 November 2025, London
Dr Huw Jones, CEO of TheraCryf, said:
"As we mark World Mental Health Day, we are very much aware of the impact mental health conditions have on quality of life for sufferers and their families. We are on track with our work to enable our orexin-1 blocker to be used in clinical trials in under a year from now. The promise of these potential medicines is made very clear in the recent European Biopharma Review article and we look forward to reminding the industry and investors of the opportunity and plans for our lead programme during the upcoming conference season."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.